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A 70-year-old female patient underwent thyroidecto-
my and thyroablative radioiodine treatment for folli-
culary thyroid cancer with pulmonary metastases
(pT1, NO, M1). For thyroid hormone replacement
therapy, serum thyroid-stimulating hormone (TSH)
concentrations were aimed to be below the lower
limit of quantification of the assay (-0.03 mU/mL)
with concentrations of free thyroxine and free triio-
dothyronine within the reference range. For TSH
measurements, the Elecsys immunoanalyzer system
(Roche Diagnostics, Mannheim, Germany) was used
in the routine endocrinological laboratory of our insti-
tute. TSH suppression is usually achieved with daily
thyroxine doses of approximately 1.5 and 2.0 mg/kg.
In the patient reported herein, the starting dose of
150 mg/day was repeatedly increased, as TSH was
constantly found detectable. Under a dose of 300 mg
thyroxine/day, a TSH concentration of 0.2 mU/mL was
measured. At this time, free serum thyroxine was
increased with 2.9 ng/dL (37.33 pmol/L) (reference
range: 0.9–1.9 ng/dL (11.58–24.46 pmol/L) and the
patient complained about symptoms consistent with
thyrotoxicosis. The constellation of hyperthyroid
symptoms along with increased thyroid hormone
concentrations in the presence of TSH levels only
slightly below the normal range was found implausi-
ble. Therefore, TSH was re-analyzed using a different
immunoassay system, implemented in the short turn-
around time laboratory of the institute (Centaur TSH
assay, Bayer Diagnostics, Tarrytown, NY, USA). Using
this assay, TSH levels were below the lower limit of
quantification. Consequently, interference of TSH
measurement was noted in this case, and the dosage
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of thyroxine substitution was reduced to 200 mg/day,
resulting in euthyroidism. For further follow-up, the
Centaur immunoanalyzer system was used for sam-
ples from this patient.
Tests of the patient’s serum for human anti-mouse
antibodies and for rheumatoid factors were negative.
When analyzing another serum sample from this
patient during a follow-up visit 3 years after our first
observation, again only slightly decreased TSH levels
were reported using the Roche Elecsys analyzer
(0.16 mU/mL), while TSH remained undetectable with
the Bayer Centaur assay.
It is well recognized that all immunoassays are sub-
jected to interferences (1, 2). Today, immunologic
interference is probably rare compared to some years
ago, owing to the addition of blocking agents to the
reagent mixtures; however, these interferences are
not yet fully resolved. Analytical interference is typi-
cally suspected if extremely high or low results are
observed; the presence of interference resulting in
more or less normal values – as was the case in our
patient – is probably detected in far less cases. Nev-
ertheless, in the case described here, assay interfer-
ence resulted in a relevant but fortunately reversible
complication (iatrogenic hyperthyroidism).
Despre´s and Grant (2) reviewed the clinical conse-
quences of failure to recognize interferences in thy-
roid assays. They reviewed the nature of these
disturbances; their occurrence, prevalence, and detec-
tion; and the clinical consequences of the failure to
recognize such interference. Mostly, heterophilic anti-
bodies are involved in TSH assay disturbance, espe-
cially human anti-mouse antibodies and rheumatoid
factors can cause interferences by immunoglobulin
aggregation, and (or) cross-linking of both capture
and signal antibodies (3).
The authors claimed that only a minority of samples
demonstrate substantial thyroid assay interferences
(2).
Ismail et al. (4) studied 5310 patients with inconsis-
tent TSH results referring to clinical details and ana-
lytical results. The samples were re-tested in three
follow-up assays (doubling dilutions assay, blocking
agents, and repeat analyses using another assay).
Incorrect analytical results due to heterophilic anti-
bodies were found in only 28 samples (0.53% of all
samples). The study showed that none of the three
follow-up procedures could exclude interferences
with total confidence. Thus, in most cases the source
of immunoassay interference cannot be specified.
The case described here should encourage physic-
ians to communicate inconsistent test results to the
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responsible clinical laboratory units. In suspect anal-
yses, applying an alternative assay is probably the
best method to disclose immunoassay interferences
in individual cases. Thus, availability of alternative
methods is most desirable for key clinical chemistry
analytes. Availability of such an alternative assay
within an individual laboratory is clearly an exception,
but shipment of samples to co-operating institutions
should be institutionalized in such cases (5, 6). Testing
the linearity of dilution may be another method to dis-
close assay interferences.
References
1. Bjerner J, Børmer OP, Nustad K. The war on heterophilic
antibody interference. Clin Chem 2005;51:9–11.
2. Despre´s N, Grant A. Antibody interference in thyroid
assays: a potential for clinical misinformation. Clin Chem
1998;44:440–54.
3. Bjerner J, Olsen KH, Børmer OP, Nustad K. Human hete-
rophilic antibodies display specificity for murine IgG sub-
classes. Clin Biochem 2005;38:465–72.
4. Ismail A, Walker PL, Barth JH, Lewandowski KC, Jones R,
Burr WA. Wrong biochemistry results: two case reports
and observational study in 5310 patients on potentially
misleading thyroid-stimulating hormone and gonadotro-
pin immunoassay results. Clin Chem 2002;48:2023–9.
5. Jahagirdar VR, Strouhal P, Holder G, Gama R, Singh BM.
Thyrotoxicosis factitia masquerading a recurrent Graves’
disease: endogenous antibody immunoassay interfer-
ence, a pitfall for the unwary. Ann Clin Biochem 2008;45:
325–7.
6. Monchamp T, Chopra IJ, Wah DT, Butch AW. Falsely ele-
vated thyroid hormone levels due to anti-sheep antibody
interference in an automated electrochemiluminescent
immunoassay. Thyroid 2007;17:271–5.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 14.11.13 15:32
